Milestone Pharmaceuticals (MIST) Net Income (2018 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly Net Income came in at -$15.0 million in Q3 2022, down 5.66% YoY from -$15.9 million in Q3 2021, and up 10.57% on a QoQ basis from -$16.8 million in Q2 2022.
Milestone Pharmaceuticals (MIST) Net Income (2018 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 5 years of Net Income data on file, last reported at -$15.0 million in Q3 2022.
- Quarterly Net Income fell 5.66% year-over-year to -$15.0 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was -$15.0 million (up 68.63% YoY) and the FY2021 annual result came in at -$42.9 million, up 14.24% from the prior year.
- Net Income grew to -$15.0 million in Q3 2022, from -$16.8 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $770000.0 in Q2 2021 to a low of -$18.3 million in Q4 2019.
- A 5-year average of -$11.3 million and a median of -$12.7 million in 2019 frame the typical range for Net Income.
- Annual changes were most pronounced in 2021 — Net Income soared 105.93% — and 2022, when it plunged 2282.6%.
- Tracing MIST's Net Income over 5 years: stood at -$9.7 million in 2018, then sank by 88.21% to -$18.3 million in 2019, then surged by 52.61% to -$8.7 million in 2020, then sank by 94.83% to -$16.9 million in 2021, then advanced by 10.98% to -$15.0 million in 2022.
- The last three Net Income figures came in at -$15.0 million (Q3 2022), -$16.8 million (Q2 2022), and -$16.9 million (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Milestone Pharmaceuticals | 42.70 Mn | -128.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -15.03 Mn |
| Jun 30, 2022 | -16.81 Mn |
| Dec 31, 2021 | -16.88 Mn |
| Sep 30, 2021 | -14.23 Mn |
| Jun 30, 2021 | 770,000.00 |
| Mar 31, 2021 | -12.51 Mn |
| Dec 31, 2020 | -8.67 Mn |
| Sep 30, 2020 | -11.98 Mn |
| Jun 30, 2020 | -12.98 Mn |
| Mar 31, 2020 | -16.34 Mn |
| Dec 31, 2019 | -18.29 Mn |
| Sep 30, 2019 | -12.83 Mn |
| Jun 30, 2019 | -13.66 Mn |
| Mar 31, 2019 | -10.45 Mn |
| Dec 31, 2018 | -9.72 Mn |
| Sep 30, 2018 | -5.70 Mn |
| Jun 30, 2018 | -3.59 Mn |
| Mar 31, 2018 | -4.18 Mn |